

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

| | |
|------------------------|-----------------|
| Effective Date: | 3/1/2024 |
|------------------------|-----------------|

[POLICY RATIONALE DISCLAIMER POLICY HISTORY](#)

[PRODUCT VARIATIONS DEFINITIONS CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND BENEFIT VARIATIONS REFERENCES](#)

I. POLICY

Lung transplantation may be considered **medically necessary** for carefully selected individuals with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy (see Policy Guidelines)

A lobar lung transplant from a living or deceased donor may be considered **medically necessary** for carefully selected members with end-stage pulmonary disease (see Policy Guidelines).

Lung or lobar lung retransplantation after a failed lung or lobar lung transplant may be considered **medically necessary** in individuals who meet criteria for lung transplantation.

Lung or lobar lung transplantation is considered **investigational** in all other situations, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

POLICY GUIDELINES

Contraindications

Potential contraindications subject to the judgment of the transplant center:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to lung disease
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Policy specific:

- Coronary artery disease not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function*; or
- Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.

*Some individuals may be candidates for combined heart-lung transplantation (see MP 9.014).

Individuals must meet United Network for Organ Sharing (UNOS) guidelines for Lung Allocation Score (LAS) greater than zero.

Lung Specific Guidelines

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

Bilateral lung transplantation is typically required when chronic lung infection disease is present, i.e., associated with cystic fibrosis and bronchiectasis. Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.

Bronchiolitis obliterans is associated with chronic lung transplant rejection, and thus may be the etiology of a request for lung retransplantation.

Cross-references:

MP 8.008 Outpatient Pulmonary Rehabilitation

MP 9.014 Heart/Lung Transplant

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

Solid organ transplantation offers a treatment option for patients with different types of endstage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life. Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

LUNG TRANSPLANT

In 2022, 42,880 transplants were performed in the United States procured from 14,900 deceased donors and 6,400 living donors. Lung transplants were the fourth most common procedure with 2,692 transplants performed from both deceased and living donors in 2022.

End-stage lung disease may derive from different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, α_1 -antitrypsin deficiency, and idiopathic pulmonary arterial hypertension. Before consideration for transplant, patients should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for chronic obstructive pulmonary disease. Lung or lobar lung transplantation is an option for patients with end-stage lung disease despite these measures.

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only 1 lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor's lung is excised, sized appropriately for the recipient's thoracic dimensions, and transplanted. Donors for lobar transplant have primarily been living-related donors, with 1 lobe obtained from each of 2 donors (generally friends or family members) in cases for which bilateral transplantation is required. There are also cases of cadaver lobe transplants.

Potential recipients who are 12 years of age and older are ranked according to the Lung Allocation Score. A score may range between 0 and 100 and incorporates predicted survival after transplantation and predicted survival on the waiting list; the Lung Allocation Score takes into consideration the patient's disease and clinical parameters. The waiting list incorporates the Lung Allocation Score, geography, and blood type classifications. Children younger than 12 years old receive priority for lung allocation. Under this system, children younger than 12 years old with respiratory lung failure and/or pulmonary hypertension who meet criteria are considered "priority 1", and all other candidates in the age group are considered "priority 2". A lung review board has the authority to adjust scores on appeal for adults and children.

Potential Contraindications to Transplantation

Malignancy

Malignancies are common after lung transplantation, with 21% and 40% of patients reporting 1 or more malignancies at 5 and 10 years posttransplantation, respectively. Skin cancer occurred most frequently, and lymphoproliferative disorders were the malignancies most associated with morbidity posttransplantation.

Human Immunodeficiency Virus Infection

Current OPTN policy permits human immunodeficiency virus (HIV)-positive transplant candidates. The 2020 US Public Health Service guideline also allows for transplantations in HIV-positive recipients with proper screenings and effective regimens for HIV infections; it recommended that all transplant candidates receive HIV, hepatitis b virus (HBV), and hepatitis C virus (HCV) testing during hospital admission for transplant surgery.⁵In 2022, the US Public Health Service published updated guidance for testing transplant candidates aged less than 12 years of age. ⁶ They recommended that children less than 12 years of age who have received postnatal infectious disease testing are exempt from repeat pretransplant HIV, HBV, and HCV testing during hospital admission for transplant surgery.

The British HIV Association and the British Transplantation Society (2017) updated their guidelines on kidney transplantation in patients with HIV disease. These criteria for adding a patient to the waitlist may be extrapolated to other organs:

- Adherent with treatment, particularly antiretroviral therapy
- Cluster of Differentiation 4 count greater than 100 cells/mL (ideally >200 cells/mL) for at least 3 months
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least 6 months
- No opportunistic infections for at least 6 months

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

- No history of progressive multifocal leukoencephalopathy, chronic intestinal cryptosporidiosis, or lymphoma.

Other Infections

Infection with *Burkholderia cenocepacia* is associated with increased mortality in some transplant centers, a factor that may be considered when evaluating the overall risk of transplant survival. Two articles have evaluated the impact of infection with various species of *Burkholderia* on outcomes for lung transplantation for cystic fibrosis. In a study by Murray et al (2008), multivariate Cox survival models were applied to 1026 lung transplant candidates and 528 transplant recipients. Of the transplant recipients, 88 were infected with *Burkholderia*. Among transplant recipients infected with *B. cenocepacia*, only those infected with nonepidemic strains (n=11) had significantly greater posttransplant mortality than uninfected patients (hazard ratio [HR] , 2.52; 95% confidence interval [CI], 1.04 to 6.12; p=.04). Transplant recipients infected with *Burkholderia gladioli* (n=14) also had significantly greater posttransplant mortality than uninfected patients (HR , 2.23; 95% CI, 1.05 to 4.74; p=.04). When adjustments for specific species or strains were included, the Lung Allocation Scores of *Burkholderia multivorans*-infected transplant candidates were comparable with uninfected candidate scores, and scores for patients infected with nonepidemic *B. cenocepacia* or *B. gladioli* were lower. In a smaller study of 22 patients colonized with *Burkholderia cepacia* complex who underwent lung transplantation in 2 French centers, Boussaud et al (2008) reported that the risk of death by univariate analysis was significantly higher for the 8 patients infected with *B. cenocepacia* than for the other 14 colonized patients (11 of whom had *B. multivorans*).

An analysis of international registry data by Yusen et al (2016) found that non-cytomegalovirus (CMV) infection is a major cause of mortality within 30 days of a lung transplant in adults. A total of 655 (19%) of 3424 deaths after transplants between 1990 and 2015 were due to non-CMV infection. Only 3 (0.1%) of the deaths were due to CMV infection.

REGULATORY STATUS

Solid organ transplants are a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation title 21, parts 1270 and 1271. Solid organs used for transplants are subject to these regulations.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have end-stage pulmonary disease who receive lung transplantation, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. International registry data on a large number of patients receiving lung transplantation (>50,000) found relatively high patient survival rates, especially among patients who survived the first year posttransplant. After adjusting for potential confounding factors, survival did not differ significantly after single- or double-lung transplant. Lung transplantation may be the only option for some patients with end-

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

stage lung disease. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have end-stage pulmonary disease who receive lobar lung transplantation, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. There are less data on lung lobar transplants than on whole-lung transplants, but several case series have reported reasonably similar survival outcomes between the procedures, and lung lobar transplants may be the only option for patients unable to wait for a whole-lung transplant. A 2017 systematic review found 1-year survival rates in the available published studies ranging from 50% to 100%. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a prior lung or lobar transplant who meet criteria for a lung transplant who receive a lung or lobar lung retransplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, treatment-related mortality and morbidity. Data from registries and case series have found favorable outcomes with lung retransplantation in patients who meet criteria for initial lung transplantation. Given the exceedingly poor survival without retransplantation of patients who have exhausted other treatments, evidence of a moderate level of posttransplant survival is sufficient in this patient population. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

CADAVER refers to a dead body or corpse.

END-STAGE refers to the final phase of a disease process.

LOBE is a well-defined part of an organ separated by boundaries, especially glandular organs and the brain.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

| Procedure Codes | | | | | | | |
|-----------------|-------|-------|-------|-------|-------|-------|-------|
| S2060 | S2061 | 32850 | 32851 | 32852 | 32853 | 32854 | 32855 |
| 32856 | | | | | | | |

| ICD-10-CM Diagnosis Codes | Description |
|---------------------------|---|
| C96.6 | Unifocal Langerhans-cell histiocytosis |
| D86.0 | Sarcoidosis of lung |
| D86.2 | Sarcoidosis of lung with sarcoidosis of lymph nodes |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| E84.8 | Cystic fibrosis with other manifestations |
| E88.01 | Alpha-1-antitrypsin deficiency |
| I26.01 | Septic pulmonary embolism with acute cor pulmonale |
| I26.02 | Saddle embolus of pulmonary artery with acute cor pulmonale |
| I26.09 | Other pulmonary embolism with acute cor pulmonale |
| I26.90 | Septic pulmonary embolism without acute cor pulmonale |
| I26.92 | Saddle embolus of pulmonary artery without acute cor pulmonale |
| I26.93 | Single subsegmental pulmonary embolism without acute cor pulmonale |
| I26.94 | Multiple subsegmental pulmonary emboli without acute cor pulmonale |
| I26.99 | Other pulmonary embolism without acute cor pulmonale |
| I27.0 | Primary pulmonary hypertension |
| I27.2 | Other secondary pulmonary hypertension (includes pulmonary hypertension due to cardiac disease) |
| I27.21 | Secondary pulmonary arterial hypertension |
| I27.22 | Pulmonary hypertension due to left heart disease |
| I27.23 | Pulmonary hypertension due to lung diseases and hypoxia |

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

| ICD-10-CM Diagnosis Codes | Description |
|----------------------------------|--|
| I27.24 | Chronic thromboembolic pulmonary hypertension |
| I27.29 | Other secondary pulmonary hypertension |
| I27.82 | Chronic pulmonary embolism |
| I27.83 | Eisenmenger's syndrome |
| I27.89 | Other specified pulmonary heart diseases (includes Eisenmenger's syndrome) |
| J42 | Unspecified chronic bronchitis |
| J43.0 | Unilateral pulmonary emphysema [MacLeod's syndrome] |
| J43.1 | Panlobular emphysema |
| J43.2 | Centrilobular emphysema |
| J43.8 | Other emphysema |
| J44.0 | Chronic obstructive pulmonary disease with acute lower respiratory infection |
| J44.1 | Chronic obstructive pulmonary disease with (acute) exacerbation |
| J47.0 | Bronchiectasis with acute lower respiratory infection |
| J47.1 | Bronchiectasis with (acute) exacerbation |
| J84.10 | Pulmonary fibrosis, unspecified |
| J84.112 | Idiopathic pulmonary fibrosis |
| J84.170 | Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere |
| J84.178 | Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere |
| J84.81 | Lymphangiomyomatosis |
| J98.2 | Interstitial emphysema |
| J98.3 | Compensatory emphysema |
| M34.81 | Systemic sclerosis with lung involvement |
| P27.1 | Bronchopulmonary dysplasia originating in the perinatal period |
| Q33.4 | Congenital bronchiectasis |
| Z86.711 | Personal history of pulmonary embolism |

IX. REFERENCES

[TOP](#)

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. *Ann Transl Med.* Oct 2018; 6(20): 409. PMID 30498736
2. *Transplant trends.* United Network for Organ Sharing website.
3. *Organ Procurement and Transplantation Network (OPTN). Policy 10: Allocation of Lungs.* Updated April 28, 2022
4. Yusen RD, Christie JD, Edwards LB, et al. *The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report-*

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

-2013; focus theme: age. *J Heart Lung Transplant*. Oct 2013; 32(10): 965-78. PMID 24054805

5. Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. *MMWR Recomm Rep*. Jun 26 2020; 69(4): 1-16. PMID 32584804
6. Free RJ, Levi ME, Bowman JS, et al. Updated U.S. Public Health Service Guideline for testing of transplant candidates aged 12 years for infection with HIV, hepatitis B virus, and hepatitis C virus - United States, 2022. *Am J Transplant*. Sep 2022; 22(9): 2269-2272. PMID 36039545
7. Working Party of the British Transplantation Society. *Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines*. Macclesfield, UK: British Transplantation Society; 2017.
8. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with *Burkholderia cepacia* complex. *Am J Transplant*. May 2008; 8(5): 1025-30. PMID 18318775
9. Murray S, Charbeneau J, Marshall BC, et al. Impact of burkholderia infection on lung transplantation in cystic fibrosis. *Am J Respir Crit Care Med*. Aug 15 2008; 178(4): 363-71. PMID 18535253
10. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with *Burkholderia cepacia* complex: results from two French centres. *Thorax*. Aug 2008; 63(8): 732-7. PMID 18408050
11. Yusef RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10): 1170-1184. PMID 27772669
12. Paraskeva MA, Edwards LB, Levvey B, et al. Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant*. Mar 2018; 37(3): 323-331. PMID 28320631
13. Goldfarb SB, Levvey BJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10): 1196-1205. PMID 27772671
14. Thabut G, Christie JD, Kremers WK, et al. Survival differences following lung transplantation among US transplant centers. *JAMA*. Jul 07 2010; 304(1): 53-60. PMID 20606149
15. Black MC, Trivedi J, Schumer EM, et al. Double lung transplants have significantly improved survival compared with single lung transplants in high lung allocation score patients. *Ann Thorac Surg*. Nov 2014; 98(5): 1737-41. PMID 25110334
16. Yu H, Bian T, Yu Z, et al. Bilateral Lung Transplantation Provides Better Long-term Survival and Pulmonary Function Than Single Lung Transplantation: A Systematic Review and Meta-analysis. *Transplantation*. Dec 2019; 103(12): 2634-2644. PMID 31283687

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

17. Yusen RD, Shearon TH, Qian Y, et al. Lung transplantation in the United States, 1999-2008. *Am J Transplant.* Apr 2010; 10(4 Pt 2): 1047-68. PMID 20420652
18. Shafii AE, Mason DP, Brown CR, et al. Too high for transplantation? Single-center analysis of the lung allocation score. *Ann Thorac Surg.* Nov 2014; 98(5): 1730-6. PMID 25218678
19. Date H. Update on living-donor lobar lung transplantation. *Curr Opin Organ Transplant.* Oct 2011; 16(5): 453-7. PMID 21836512
20. Eberlein M, Reed RM, Chahla M, et al. Lobar lung transplantation from deceased donors: A systematic review. *World J Transplant.* Feb 24 2017; 7(1): 70-80. PMID 28280698
21. Barr ML, Schenkel FA, Bowdish ME, et al. Living donor lobar lung transplantation: current status and future directions. *Transplant Proc.* Nov 2005; 37(9): 3983-6. PMID 16386604
22. Date H, Sato M, Aoyama A, et al. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients. *Eur J Cardiothorac Surg.* Jun 2015; 47(6): 967-72; discussion 972-3. PMID 25228745
23. Date H, Shiraishi T, Sugimoto S, et al. Outcome of living-donor lobar lung transplantation using a single donor. *J Thorac Cardiovasc Surg.* Sep 2012; 144(3): 710-5. PMID 22717276
24. Slama A, Ghanim B, Klikovits T, et al. Lobar lung transplantation--is it comparable with standard lung transplantation? *Transpl Int.* Sep 2014; 27(9): 909-16. PMID 24810771
25. Kilic A, Beaty CA, Merlo CA, et al. Functional status is highly predictive of outcomes after redo lung transplantation: an analysis of 390 cases in the modern era. *Ann Thorac Surg.* Nov 2013; 96(5): 1804-11; discussion 1811. PMID 23968759
26. Kawut SM. Lung retransplantation. *Clin Chest Med.* Jun 2011; 32(2): 367-77. PMID 21511096
27. Biswas Roy S, Panchanathan R, Walia R, et al. Lung Retransplantation for Chronic Rejection: A Single-Center Experience. *Ann Thorac Surg.* Jan 2018; 105(1): 221-227. PMID 29100649
28. Organ Procurement and Transplantation Network (OPTN). National Data. n.d.
29. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* Nov 2021; 40(11): 1349-1379. PMID 34419372
30. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* Mar 15 2011; 183(6): 788-824. PMID 21471066
31. Raghu G, Rochweg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med.* Jul 15 2015; 192(2): e3-19. PMID 26177183
32. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *Eur Respir J.* Dec 2014; 44(6): 1479-503. PMID 25359357
33. Centers for Medicare & Medicaid. *Transplant.* Updated December 01, 2021

MEDICAL POLICY

| | |
|----------------------|---------------------------------------|
| POLICY TITLE | LUNG AND LOBAR LUNG TRANSPLANT |
| POLICY NUMBER | MP 9.015 |

- 34. Hachem RR. Lung transplantation: General guidelines for recipient selection. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; updated September 8, 2022. Literature review current through November 2022.
- 35. Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. *J Cyst Fibros.* 2019;18(3):321-333. doi:10.1016/j.jcf.2019.03.002
- 36. Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.03.07, Lung and Lobar Lung Transplant. September 2023.

X. POLICY HISTORY

[TOP](#)

| | |
|-----------------|--|
| MP 9.015 | 02/11/20 Consensus review. References and coding reviewed. No changes to policy statements. |
| | 9/1/20 Administrative update. Added ICD 10 J84.178 |
| | 5/3/21 Consensus review. No change to policy statement. References updated. Revised Description/Background section. Added diagnosis code I27.0 and J84.170. Removed J84.17. |
| | 12/8/2022 Minor review. Deleted the indications table from policy statement. Updated FEP, background, definitions, coding table, and references. |
| | 8/29/2023 Consensus review. No change to policy statement. Background updated. References reviewed and updated. No coding changes. |

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies